Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Galapagos N.V.
Galapagos N.V. News
Galapagos N.V. Quantitative Score
About Galapagos N.V.
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Galapagos N.V. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Galapagos N.V. Financials
Table Compare
Compare GLPG metrics with: | |||
|---|---|---|---|
Earnings & Growth | GLPG | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GLPG | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GLPG | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GLPG | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Galapagos N.V. Income
Galapagos N.V. Balance Sheet
Galapagos N.V. Cash Flow
Galapagos N.V. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Galapagos N.V. Executives
| Name | Role |
|---|---|
| Mr. Henry Gosebruch | Chief Executive Officer & Executive Director |
| Mr. Aaron L. Cox | Chief Financial Officer |
| Mr. Fred W. Blakeslee II | Executive Vice President & General Counsel |
| Dr. Jeevan Shetty | Head of Clinical Development Oncology |
| Mr. Patrik Ringblom | Head of Strategy & US Lead |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Henry Gosebruch | Chief Executive Officer & Executive Director | Male | -- | |
| Mr. Aaron L. Cox | Chief Financial Officer | Male | 1983 | -- |
| Mr. Fred W. Blakeslee II | Executive Vice President & General Counsel | Male | -- | |
| Dr. Jeevan Shetty | Head of Clinical Development Oncology | -- | ||
| Mr. Patrik Ringblom | Head of Strategy & US Lead | Male | -- |